Search clinical trials for: PF-06650808

Total 1296 results

Pfizer

Recruiting

A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.

Migraine

China
Pfizer

Completed

B0151005 Open-Label Extension Study (ANDANTE II)

Crohn's Disease

United States, Denmark, Israel, Ireland, Australia, Czechia, Canada, United Kingdom, Hungary, Germany, New Zealand, Brazil, Switzerland, Belgium, France, Italy
Kathryn Wagner
Pfizer

Completed

A Trial of PF-06252616 in Ambulatory Participants With LGMD2I

LGMD2I

United States
Pfizer

Completed

PF-00489791 For The Treatment Of Raynaud's

Peripheral Vascular Disease | Raynaud's Disease

Spain, United States, Czechia, Hungary, Poland, Korea, Republic of, Canada, Mexico, Germany, Colombia, Sweden
Conatus Pharmaceuticals Inc.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Terminated

Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy (AH)

Alcoholic Hepatitis

United States
Pfizer

Withdrawn

A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer

Advanced EGFRm (Del 19 or L858R +/- T790M) NSCLC
Pfizer

Terminated

A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

Advanced Non-Hematologic Malignancies

United States, United Kingdom
Pfizer

Terminated

A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin

Cachexia

United States
Pfizer

Terminated

Efficacy, Safety and Tolerability of PF-06687234 as Add-on Therapy to Infliximab in Active UC Subjects Not in Remission.

Ulcerative Colitis

United States, Australia, Italy, Korea, Republic of, Belgium, Israel, Turkey, Saudi Arabia, Germany, Serbia
Bausch & Lomb Incorporated

Completed

A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension.

Primary Open Angle Glaucoma | Ocular Hypertension

Japan
Pfizer

Completed

A First in Human Study to Evaluate Safety, Tolerability, and Pharmacology of PF-06826647 in Healthy Subjects and Subjects With Plaque Psoriasis

Plaque Psoriasis

United States
Pfizer

Completed

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

Diabetes Mellitus, Type 2

Taiwan, United States, Hungary, Canada, Slovakia, India, Bulgaria
Pfizer

Active, not recruiting

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

Eczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, Unspecified

United States, Canada, Czechia, Poland
Pfizer

Terminated

A Study of ARRY-371797 (PF-07265803) in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation (REALM-DCM)

Dilated Cardiomyopathy | Lamin A/C Gene Mutation

United States, Spain, Canada, Belgium, Italy, Argentina, Mexico, Netherlands, Norway, United Kingdom
University of Oxford

Completed

PF-04995274 and Emotional Processing in Treatment Resistant Depression (RESTART)

Treatment Resistant Depression | Depression, Unipolar

United Kingdom
Shire

Terminated

Efficacy and Safety Study of Ontamalimab as Induction Therapy in Participants With Moderate to Severe Crohn's Disease (CARMEN CD 306) (CARMEN CD 306)

Crohn's Disease

Spain, United States, Korea, Republic of, Hungary, Turkey, Belgium, Bulgaria, Argentina, Greece, New Zealand, Bosnia and Herzegovina, Colombia, Estonia, Ireland, Japan, Lebanon, Mexico, Portugal, Slovakia, Ukraine
Pfizer
JANSSEN Alzheimer Immunotherapy Research & Development, LLC

Completed

Study Evaluating The Safety Of AAB-003 (PF-05236812) In Subjects With Alzheimer's Disease

Alzheimer's Disease

United States, Korea, Republic of
Jules Bordet Institute

Withdrawn

Biomarker Research Study for PF-03084014 in cHEmoresistant Triple-negative Breast cAncer (RHEA)

Breast Cancer

Belgium, France
Conatus Pharmaceuticals Inc.

Completed

PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers

Kidney Diseases | Renal Insufficiency | Renal Impairment | Kidney Disease

United States
Pfizer

Terminated

Multiple Dose Study Of PF-05231023 In Obese Adult Subjects

Type 2 Diabetes Mellitus (T2DM)

United States
Pfizer

Completed

Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects

Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia (CML)

Singapore
Pfizer

Completed

Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects

Healthy

United States
Pfizer

Withdrawn

A Study Of Oral PF-01913539 In Patients With Mild To Moderate Alzheimer's Disease

Dementia | Alzheimer's Disease | Dimebon | Investigational Drug
Pfizer

Completed

PF-3512676 (CPG 7909) Injection For Patients Who Completed An Oncology Study Using PF-3512676 (CPG 7909)

Melanoma | Carcinoma, Renal Cell | Breast Neoplasms | Carcinoma, Non-Small-Cell Lung | Lymphoma, T-Cell

United States, Germany
Pfizer

Completed

CPG 7909 in Patients With Cutaneous T-Cell Lymphoma

Lymphoma, T-Cell, Cutaneous
Pfizer

Completed

Effect of PF-00734200 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

Canada, United States, Korea, Republic of, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Multiple Myeloma

United States
Pfizer

Active, not recruiting

A Study to Learn How the Study Medicine Called PF-07275315 Works in Healthy People

Healthy Volunteers

United States, Belgium
M.D. Anderson Cancer Center
Pfizer; ISA Pharmaceuticals B.V.

Completed

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

Oropharyngeal Cancer | Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites | Malignant Neoplasms of Lip Oral Cavity and Pharynx

United States
Shire

Completed

A Study To Monitor Long-Term Treatment With PF-00547659 (OPERA II)

Crohn's Disease

Korea, Republic of, United States, Spain, France, Serbia, Netherlands, Germany, Japan, Austria, Belgium, Poland, Canada, Norway, Slovakia, South Africa
Pfizer

Terminated

A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

United States
Pfizer

Recruiting

PF-07104091 as a Single Agent and in Combination Therapy

Breast Cancer | Small Cell Lung Cancer | Ovarian Cancer

China, United States, Japan, Mexico
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06882961 in Adults With Obesity

Obesity

United States, Taiwan, Canada, Japan
Pfizer

Recruiting

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

Melanoma | Neoplasms | Renal Cell Carcinoma | Non-small-cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck | Urothelial Carcinoma | Colorectal Carcinoma | Ovarian Carcinoma

Puerto Rico, Japan, United States
PETHEMA Foundation

Recruiting

Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes

Multiple Myeloma in Relapse

Spain
Pfizer

Available

Elranatamab Expanded Access Protocol in Adults With Relapsed/Refractory Multiple Myeloma (MAGNETISMM17)

Multiple Myeloma

United States, Canada
Pfizer

Terminated

PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors

Melanoma | Carcinoma, Renal Cell | Breast Neoplasms | Liver Neoplasms | Colorectal Neoplasms | Pancreatic Neoplasms | Mesothelioma | Neoplasms, Squamous Cell | Prostate Neoplasms

United States
Pfizer

Completed

Multiple Dose Study Of PF-04937319 In Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2 | NIDDM

United States
Medela AG

Completed

Impact of Breast Shield Designs on Dynamics of Breast Pumping (BSD)

Lactation

Switzerland
Pfizer

Completed

Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Alopecia Areata

United States, Canada, Australia
Pfizer

Active, not recruiting

A Preliminary Study to Evaluate PF-07264660 in Healthy Participants

Healthy

United States
Cerevel Therapeutics, LLC

Recruiting

A Multiple Dose Trial of Emraclidine in Elderly Participants and in Participants With Dementia Due to Alzheimer's Disease

Healthy Participants | Alzheimer's Disease Dementia

United States
Pfizer

Active, not recruiting

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Non-small-cell Lung Cancer | Advanced Malignancies

China, Korea, Republic of, Taiwan, Japan, Russian Federation, Ukraine
Pfizer

Completed

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Ovarian Cancer | Non-Small Cell Lung Cancer | Squamous Cell Carcinoma of the Head and Neck

United States, Spain
Vicore Pharma AB
Curebase Inc.

Active, not recruiting

Controlled Investigation to Evaluate Impact of dCBT on Psychological Symptom Burden in Adult Subjects With PF (COMPANION)

Generalized Anxiety Disorder | Pulmonary Fibrosis

United States
Pfizer

Terminated

A Study of Marstacimab to Compare Prefilled Pen (PFP) Device to Prefilled Syringe (PFS) Device

Healthy Volunteers

Belgium
Pfizer

Completed

Safety and Efficacy of EXC 001 in Subjects Who Have Participated in Prior Studies of EXC 001

Reduction in Severity of Skin Scarring

United States
Stanford University

Withdrawn

PROMs To Improve Care- Standardized vs Patient Specific

Hand Injuries
Pfizer

Completed

Bioavailability Study of PF-06651600 Formulations in Healthy Participants

Healthy Volunteers

Belgium
Pfizer

Terminated

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

Huntington's Disease

United States, Germany, Poland, United Kingdom, Canada

Search clinical trials for: PF-06650808

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ecuador

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations